Flash Finance

Strides Pharma Science LimitedSTARCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Mar 2026 13 quarters of data
Consolidated Standalone
₹1,045.20
MCap ₹9,634 Cr · P/E 52.6
Strides Pharma Science Limited — Stock analysis & AI research Strides Pharma Science Limited — Seasonality — best & worst months Strides Pharma Science Limited — Technical indicators & charts Strides Pharma Science Limited — Technical setup — score, trend, support & resistance Strides Pharma Science Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 Stocks Cheaper Than Their Industry📋 High Profit Growth Stocks📋 Promoters Increasing Stake 📈 20-Day Breakdown Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹606 Cr
Sales · Mar 2026
+9.0% YoY
₹74 Cr
Operating Profit · Mar 2026
+8.9% YoY
12.2%
OPM % · Mar 2026
+0.0% YoY
₹16 Cr
Net Profit · Mar 2026
-0.8% YoY
₹1.77
EPS · Mar 2026
+1.1% YoY

📝 Strides Pharma Science Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Strides Pharma Science Limited reported revenue of ₹606 crore for the quarter ended March 2026 (Q4 FY26), up 9.0% from ₹556 crore in the same quarter last year, and down 7.7% sequentially over the December 2025 quarter.

Net profit fell 0.8% year-on-year to ₹16 crore, from ₹16 crore. Earnings per share (EPS) came in at ₹1.77.

Operating profit stood at ₹74 crore — an operating margin (OPM) of 12.2%, compared with 12.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Strides Pharma Science Limited posted revenue of ₹2,298 crore, a growth of 3.8% over FY25, with a net profit of ₹183 crore (up 264.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,298 crore with a net profit of ₹183 crore.

Valuation snapshot

At the current price of ₹1,045.20, STAR has a market capitalisation of ₹9,634 crore and a trailing P/E of about 52.6.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 2nd-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 29.00%, foreign institutional investors (FIIs) 27.98%, domestic institutional investors (DIIs) 15.51%, the government 0.01%, public shareholders 27.51% of Strides Pharma Science Limited.

Promoter holding rose from 27.91% to 29.00% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹9,634 Cr
Current Price ?
₹1,045.2
P/E ?
52.56above ind
Industry P/E ?
37.20
P/B ?
2.93
P/S ?
4.19
P/FCF ?
83.05
Enterprise Value ?
₹10,818 Cr
EV/EBITDA ?
38.06
PEG ?
0.50
Earnings Yield ?
1.8%
Dividend Yield ?
0.38%
Profitability & Returns
Sales (TTM) ?
₹2,298 Cr
OPM ?
12.4%
Profit after tax (TTM) ?
₹183 Cr
EPS (TTM) ?
₹19.88
ROCE ?
7.0%
ROE ?
5.6%
ROA ?
3.4%
Growth
Sales — latest qtr ?
₹606 Cr
PAT — latest qtr ?
₹16 Cr
YoY qtr sales growth ?
9.0%
YoY qtr profit growth ?
-0.8%
Sales growth (3y) ?
6%
Sales growth (5y) ?
3%
Profit growth (3y) ?
106%
Profit growth (5y) ?
20%
Financial Health
Debt ?
₹1,184 Cr
Debt to Equity ?
0.36
Interest Coverage ?
1.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
29.00%
Change in promoter holding ?
0.70%
Pledged percentage ?
N/A
Market
Return 3 months ?
-2.8%
Return 6 months ?
4.5%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 564475553380618586520551556499536657606 +9.0% -7.7%
Operating Profit 11956381916655746867628174 +8.9% -8.6%
Other Income 11121960308242122141034 -67.0% -96.1%
Interest 43374236474842342930292727 -8.0% +0.0%
Depreciation 23212322212221212222222225 +11.8% +13.6%
Profit Before Tax 65944536142128162513527 -4.7% -80.0%
Net Profit 62813544151516133212216 -0.8% -86.9%
EPS 6.910.89-0.75-0.045.650.261.881.621.751.453.4813.231.77 +1.1% -86.6%
OPM % 21.1% 11.8% 6.9% 0.3% 14.7% 11.3% 10.6% 13.4% 12.2% 13.5% 11.6% 12.3% 12.2% +0.0% -0.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,213 Cr ₹2,298 Cr ₹2,298 Cr +3.8%
Operating Profit ₹263 Cr ₹284 Cr ₹284 Cr +8.1%
OPM % 11.89% 12.37% 12.37% +4.0%
NPM % 2.27% 7.98% 7.98% +251.5%
Other Income ₹47 Cr ₹123 Cr ₹123 Cr +163.7%
Depreciation ₹86 Cr ₹91 Cr ₹91 Cr +5.6%
Interest ₹154 Cr ₹113 Cr ₹113 Cr -26.1%
EBIT ₹177 Cr ₹193 Cr ₹193 Cr +9.3%
PBT ₹70 Cr ₹204 Cr ₹204 Cr +191.7%
Tax ₹19 Cr ₹3 Cr ₹3 Cr -83.6%
Net Profit ₹50 Cr ₹183 Cr ₹183 Cr +264.4%
EPS ₹5.51 ₹19.93 ₹19.93 +261.7%
Material Cost ₹606 Cr ₹227 Cr ₹227 Cr -62.6%
Employee Cost ₹186 Cr ₹94 Cr ₹94 Cr -49.3%
Extraordinary Items ₹-0 Cr — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 90929292 +0.0%
Reserves 3,3653,4363,1013,191 +2.9%
Borrowings 1,4141,6881,2021,184 -1.5%
Other Liabilities 750687636928 +45.9%
Total Liabilities 5,6205,9025,0315,396 +7.3%
Fixed Assets 597747767882 +15.0%
CWIP 5510710684 -20.8%
Investments 2,4922,3641,8481,868 +1.1%
Other Assets 2,4762,6842,3112,561 +10.8%
Total Assets 5,6205,9025,0315,396 +7.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 242-14421278 -34.0%
Cash from Investing Activity -183-69-138-69 +50.0%
Cash from Financing Activity 1193-370-199 +46.2%
Net Cash Flow 7011-8610 +111.6%
Free Cash Flow 161-89269116 -56.9%
CFO/OP 142%-45%114%98% -14.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 257306248255 +2.8%
Inventory Days 168188145191 +31.7%
Days Payable 220205163225 +38.0%
Cash Conversion Cycle 205289230220 -4.3%
Working Capital Days 48418383 +0.0%
ROCE % 2%2%5%7% +40.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 28.30%27.86%27.86%27.91%27.91%29.00% +3.9%
FIIs 28.02%28.51%29.52%28.68%28.39%27.98% -1.4%
DIIs 13.30%12.98%13.02%14.44%15.41%15.51% +0.6%
Government 0.01%0.01%0.01%0.01%0.01%0.01% +0.0%
Public 30.38%30.62%29.59%28.96%28.28%27.51% -2.7%
No. of Shareholders 92,88991,20685,58986,61694,85093,336 -1.6%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Strides Pharma Science Limited's revenue in Q4 FY26?
Strides Pharma Science Limited reported revenue of ₹606 crore for the quarter ended March 2026 (Q4 FY26), up 9.0% from ₹556 crore in the same quarter last year, and down 7.7% sequentially over the December 2025 quarter.
What was Strides Pharma Science Limited's net profit in Q4 FY26?
Net profit fell 0.8% year-on-year to ₹16 crore, from ₹16 crore. Earnings per share (EPS) came in at ₹1.77.
What is STAR's market capitalisation and P/E ratio?
At the current price of ₹1,045.20, STAR has a market capitalisation of ₹9,634 crore and a trailing P/E of about 52.6.
Who owns Strides Pharma Science Limited? (shareholding pattern)
As of Sep 2026, promoters held 29.00%, foreign institutional investors (FIIs) 27.98%, domestic institutional investors (DIIs) 15.51%, the government 0.01%, public shareholders 27.51% of Strides Pharma Science Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI